Can a point-of-care urine protein assay monitor bladder cancer recurrence?

Affiliations

Editorial

Michael A O'donnell. Nat Clin Pract Oncol. 2006 Sep.

. 2006 Sep;3(9):482-3.

doi: 10.1038/ncponc0589.

¹ Department of Urology, University of Iowa, 200 Hawkins Drive, 3 RCP, Iowa City, IA 52242-1089, USA. michael-odonnell@uiowa.edu

No abstract available

Similar articles

Urinary bladder tumor markers.
Lokeshwar VB, Selzer MG. Lokeshwar VB, et al. Urol Oncol. 2006 Nov-Dec;24(6):528-37. doi: 10.1016/j.urolonc.2006.07.003. Urol Oncol. 2006. PMID: 17138134 Review.
Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, Zini E, Bartoletti R. Cai T, et al. J Urol. 2007 Nov;178(5):1906-11;discussion 1911-2. doi: 10.1016/j.juro.2007.07.041. Epub 2007 Sep 17. J Urol. 2007. PMID: 17868727
Urine detection of survivin and diagnosis of bladder cancer.
Moore M. Moore M. J Insur Med. 2001;33(2):202-3. J Insur Med. 2001. PMID: 11510521 No abstract available.
Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
Babjuk M, Soukup V, Pesl M, Kostírová M, Drncová E, Smolová H, Szakacsová M, Getzenberg R, Pavlík I, Dvorácek J. Babjuk M, et al. Urology. 2008 Apr;71(4):718-22. doi: 10.1016/j.urology.2007.12.021. Urology. 2008. PMID: 18387400 Clinical Trial.
Potential of urinary biomarkers in early bladder cancer diagnosis.
Lam T, Nabi G. Lam T, et al. Expert Rev Anticancer Ther. 2007 Aug;7(8):1105-15. doi: 10.1586/14737140.7.8.1105. Expert Rev Anticancer Ther. 2007. PMID: 18028019 Review.